Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
EDEN PRAIRIE, Minn., Sept. 21, 2017 -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today that John Erb, CEO, will be a featured presenter at the Ladenburg Thalmann 2017 Healthcare Conference at the Sofitel Hotel in New York City on September 26, 2017 at 1:30pm eastern time. Interested parties can view the Company’s presentation on its Investor tab at https://www.chf-solutions.com.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
For further information, please contact:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions Inc.
T: +1-952-345-4205
-or-
Bret Shapiro
Managing Partner
CORE IR
516 222 2560
[email protected]
www.coreir.com
Investor Relations:
CHF Solutions, Inc.
[email protected]
